Omacetaxine and azacitidine for newly diagnosed patients with MDS and excess blasts
In this video, Daniel Pollyea, University of Colorado School of Medicine, Denver, CO, comments on the potential of combining omacetaxine and azacitidine for newly diagnosed patients with myelodysplastic syndromes (MDS) and excess blasts. Dr Pollyea highlights that the clinical trial aimed to target MDS stem cells through protein synthesis inhibition, and the results show promising response rates. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
